615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II

Use of G CSF in AML patients with febrile neutropenia Friend or foe

Real world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL 2 inhibitor

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Safety and outcomes of venetoclax initiation in patients with  AML and hyperleukocytosis

Single center experience with mitoxantrone hydrochloride liposome based therapy for patients with myeloid sarcoma

Central nervous system involvement in pediatric Acute Myeloid Leukemia A comprehensive report from the AML BFM group

Real world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA Trinetx based analysis

Co mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

ASXL1 mutations are associated with adverse outcomes in european leukemianet ELN 2024 favorable risk patients with Acute Myeloid Leukemia AML treated with venetoclax VEN containing low intensity therapy LIT

Treatment intensity may alter the prognostic impact of baseline co mutations in newly diagnosed FLT3 ITD AML treated with FLT3 inhibitor based therapy

Spliceosome mutations in AML Prevalence clinical features and treatment outcomes in a contemporary cohort

Venetoclax combined with three day multi frequency decitabine DEC3 VEN as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53 mutantion

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Unmasking myeloid sarcoma A SEER database study of an underrecognized malignancy

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Comparable remission rates in therapy related and myelodysplasia related Acute Myeloid Leukemia AML versus de novo AML treated with azacitidine and venetoclax A contemporary real world study

Real world survival of IDH mutant patients in China before IDH inhibitor era A multicenter retrospective study from anhui cooperative hematology group ACHG

Extramedullary disease in AML A high risk feature beyond ELN 2022 classification

Central nervous system involvement in acute myeloid leukemia A national analysis of inpatient outcomes using the 2022 national inpatient sample

Differences in outcomes with intensive chemotherapy in AML patients according to mutational status – recent real world results

Real world treatment patterns and outcomes among patients with newly diagnosed NPM1 mutated acute myeloid leukemia in the United States

Interim analysis after 3 months of AML patients treated with venetoclax azacitidine – first effectiveness and safety data from the prospective real world vero study

Treatment initiation pattern ramp up measures and management of AML patients treated in real life in Italy with venetoclax azacitidine first interim analysis of the prospective vero study

Only young age and genetics retain prognostic value for 2 year relapse free survival in AML

Pulmonary complications in acute myelogenous leukemia in post allogenic hematopoietic stem cell transplant period and yield of bronchoalveolar lavage and biopsy single center experience

Beyond age Genomic features and treatment outcomes in older versus younger adults with Acute Myeloid Leukemia

Fractionated gemtuzumab ozogamicin GO with high dose cytarabine HiDAC based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine venetoclax AZA VEN and associated with worse outcomes in AML

Molecular mutations may influence cytokine expression and critical illness subphenotyping in septic patients with Acute Myeloid Leukemia